Foghorn Therapeutics Inc. (FHTX) financial statements and ratios from SEC XBRL: revenue $30.91M (TTM), net margin -240.3%, revenue growth 36.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $30.91M |
| Net Margin | -240.3% |
| Revenue Growth (YoY) | 36.8% |
| EPS Growth (YoY) | -25.3% |
| FCF Growth (YoY) | -15.0% |
| Price / Sales | 13.68 |
| FCF Yield | -37.5% |
| Altman Z-Score | -4.31 (distress) |
| Sector P/E (Healthcare) | 21.7 |
FHTX overview · FHTX earnings · FHTX KPIs · FHTX investor relations · FHTX ownership · FHTX peers · FHTX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.